🔗 Share this article

While the US undertakes unprecedented revisions to its immunization recommendations, an unexpected name has emerged in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by questioning coronavirus vaccines in the pandemic and has zeroed in on potential fatalities following Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Schedule

Agency leaders had intended to reveal major revisions to the childhood vaccine schedule in December, bringing the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US at odds with much of the international standard with insufficient data for public health gain. The announcement has been postponed until the new year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the event. She was just designated acting director of the FDA’s CDER, the fifth person to run the office this calendar year.

Consolidating Power at the Agency

Høeg's temporary position might represent a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad solidify control at the agency – and it suggests a renewed priority upon rolling back previously authorized vaccines at the FDA.

Høeg has repeatedly called for discontinuing certain childhood immunization guidelines in the US in order to be more similar to Denmark, a society with universal health coverage and a number of inhabitants about the size of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccination policy – usually the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Qualifications

Høeg has no obvious experience in pharmaceutical research, oversight or management, which has been standard for past directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and CBER since spring.

“She appears not to have the necessary background” for leading the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in leading a major agency. She is not an expert in pharmaceutical oversight.”

Past commissioners of the center would “grasp regulatory frameworks and the underlying principles of drug development”, noted Janet Woodcock. “Frankly, she has not acquired the kind of background that previous people who led the center have had.”

This division has an vast portfolio at the agency, she emphasized.

“Everybody just zeroes in on the novel medication approvals, but the generic drug division approves thousands of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and so forth, and every single one need to be looked after,” Woodcock noted. “The area you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a substantial leadership aspect to the role, which supervises in excess of 5,000 employees. “It is a massive administrative position, if you perform it correctly,” the former official concluded.

Agency Reaction and Contentious Policies

When asked about questions about Dr. Høeg's fitness for the role and whether this assignment represents greater collaboration among FDA leaders on vaccines, a representative said that the “questions stem from flawed assumptions”.

“Her experience is consistent with the duties of her role,” the representative stated, noting the months Høeg spent advising the FDA commissioner on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg takes over the commissioner’s new priority voucher program, a controversial rapid drug-approval program that reportedly troubled her former heads. “By what process are these medications being chosen for this fast-track system? Who takes the calls?” Dr. Howard said. “There is a lot of lack of transparency occurring at the FDA right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards more relaxed rules of all drugs, aside from shots.”

Documented Past Work on Immunizations

Concerning vaccines, Høeg has a clearer, if concerning, history, critics observe. She released a research paper using unverified crowd-sourced reports to assess the incidence of myocarditis following Covid vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the incoming government encompassed altering guidelines for recently developed shots and halting “non-essential” vaccines, she stated after the election on a online show. At the FDA, Dr. Høeg has allegedly suggested excluding adolescent males from receiving COVID-19 vaccinations.

“She’s an all-around ideologue who commences with her beliefs and tailors the evidence to fit the data in a extremely deceptive, untruthful manner,” Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with fellow contrarians, {like|